Use access key #2 to skip to page content.

The Exact Table I Pound

Recs

28

April 05, 2011 – Comments (4) | RELATED TICKERS: EXAS

For several years now I have been telling people about a company called Exact Sciences.  I will disclose that I am very long and very committed to the position long term.  In fact, the position has grown to be my largest.  A colleague today commented he would love to see the company pull back so he could buy more.  My comment, "it's going to at least $30, it's $7, just buy it." 

So, I guess I have two things today I'll talk about.  First, I'll talk briefly about Exact Sciences, EXAS.  Exact Sciences, according to research so far, has a DNA based screening test for colorectal cancer that can pick up cancer in it's earliest stages and in fact in a pre-cancerous form.  This is an extremely important test as colorectal cancer is very deadly when found late.  Under current tesing realities, it is usually found late because people simply do not want a colonscopy and FOBT/FIT doesn't work well even when peole are in compliance with testing guidelines- which they usually aren't.

A validation report on Exact's science is due soon, and an FDA study will very likely follow if the validation report is about what many, including at the company expect.  If Exact gets this test to market, likely sometime in late 2012 or 2013, the market potential is well over a billion dollars in global revenue (the company has made in roads in Europe already).  The potential market cap is into the several billions of dollars just on this test.  The kicker is that the technology that Exact has is very adaptable to other screening tests.  This company could be the next Genzyme or Genentech if it is not bought out in the next few years.  A poison pill prevents a cheap take out, so we might be witnessig the slow motion birth (Exact has been around over a decade) of a new giant.

Now, onto investment philosophy.  The guy next door down who I turned onto EXAS wants a pullback.  I do not, not really, I already own a lot of EXAS via calls and stock.  Regardless, forget the pullback potential, it's a microcap bio-tech, there is always pullback potential.  The problem I see over and over is that too many people wait for pullbacks of things they know are good ideas.  In essence sabotaging themselves.  If you know something is a good idea, at least buy a quarter position (to me that is 1.5% of a portfolio).  If you don't know something is a good idea, don't buy any.  If something you have is not actually a good idea, don't wait, just sell it unless you have a chart that tells you that in a few days you'll get a great exit opportunity, but since you don't, so just sell it.

For those who care, I have a double position in EXAS, that is, about 12% of holdings.

Do your own research, and by all means, act on it when you are sure.

4 Comments – Post Your Own

#1) On April 08, 2011 at 5:24 PM, Troy2008 (96.86) wrote:

Good analysys Kirky.

Report this comment
#2) On April 08, 2011 at 6:44 PM, Option1307 (29.98) wrote:

A colleague today commented he would love to see the company pull back so he could buy more.  My comment, "it's going to at least $30, it's $7, just buy it."

I know you have done extensive research on this company and likely know it far better than most, so I'm not here to disagree with you. In fact I agree with you that the long term potential of this is huge. However, as you state clinical trials are still a ways off and getting to market is still several years away.

Therefore I have to assume there will be at least 1 more round of dilution/raising cash and this would be a much better opportunity to buy into EXAS imo than the current price of ~$7.

Maybe EXAS is different, but I'd argue that every other small pharma/biotech has proved that shareholder dilution will always continue to take place. Especially when trying to get through clinical trials and FDA approval etc.

Hopefully one day I'll scoop up some shares of EXAS, but not at these prices.

Best of Luck!

Report this comment
#3) On April 12, 2011 at 10:16 PM, kirkydu (94.22) wrote:

Well Option, when you ASS U ME you know what you get.  There will not be anymore dilution, the company raised cash with a secondary recently through a large regional who placed the shares with their A clients at $6, which appears to be a very good floor.  The company has already been through the valley of death, I would build a position now.  Buy some stock, sell some puts.  That's what I'm doing.  I am also buying calls every few months with some of the put premium.  I have not gone on a limb and called a company a potentially life changing investment before, but this one looks like it could be, with the downside that we might only double or triple our money from here over the next few years.

Report this comment
#4) On April 13, 2011 at 12:26 AM, Option1307 (29.98) wrote:

when you ASS U ME you know what you get.

Ha, very true.

As I stated above, I realize you have done vastly more research than me in regards to EXAS, and I appreciate your willingness to share. I was just pointing out that typically you don't need to, and arguably shouldn't, "chase" baby biotech/pharmas.

The obvious caveat being that EXAS may not be a typical small biotech/pharm, that's something investors have to judge for themselves.

Again Kirk, I wish you the best of luck.

 

Report this comment

Featured Broker Partners


Advertisement